Assisi Care home

Science

The BSP Protein Platform

A research-stage program exploring proteins that act against cancer cells while sparing normal cells.

The challenge

Selectivity is the hardest problem in cancer therapy

Cancer cells come from the body’s own cells, so they share most of their machinery with healthy tissue. Treatments that hit cancer hard often hit healthy cells too, and that damage limits how well treatment can work.

Our research focuses on the narrow window where a therapy can harm cancer cells without harming the normal cells around them.

Lab photo (placeholder)

How it works

From protein to selective effect

A simplified view of the question each of our studies is built to answer.

  1. BSP proteins

    We design and study BSP proteins, a family of engineered proteins at the centre of our research.

  2. Selective recognition

    In laboratory studies, BSP proteins are designed to act on features that distinguish cancer cells from normal cells.

  3. Cancer cells affected, normal cells spared

    Our preclinical work measures cancer-cell death alongside the viability of healthy cells, the balance that matters most.

Placeholder for the science team: add a short, accurate description of the BSP mechanism of action here, at a level a non-specialist investor can follow.

Preclinical findings

What we have observed so far

Activity against cancer cells

Placeholder: summarise the cancer cell lines tested and the effect observed, with the assay used.

Add data + source

Normal cells spared

Placeholder: summarise viability of normal (non-cancerous) cells tested under the same conditions.

Add data + source

Dose response

Placeholder: describe how effect changes with dose, and the window between cancer and normal cells.

Add data + source

Next experiments

Placeholder: outline the studies planned for the next 12 to 18 months.

Add plan

All findings are preclinical. They have not been shown to be safe or effective in people.

Development stage

Where the program stands

  1. Discovery

    BSP protein candidates identified

  2. In vitro validation Now

    Selectivity tested in cell models

  3. In vivo studies

    Efficacy and safety in animal models

  4. IND-enabling

    Manufacturing, toxicology, regulatory package

  5. Clinical trials

    First studies in people

Placeholder: confirm the current stage

Intellectual property

Protecting the platform

Placeholder: describe patent applications filed or planned, and the territories covered. Only list filings that are already public.

See publications and patents

Scientific overview

Researchers and partners can request a short PDF overview of the BSP program.

Request the Overview

Interested in the BSP program?

Talk to us about research collaborations, licensing or investment.

Partner With Us Contact Us